Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study

Jorge Cortes, Lynn Huynh, Estella Mendelson, Patricia Brandt, Darshan Dalal, Maral DerSarkissian, Diego Cortina, Sahil Narkhede, Mei Sheng Duh

Research output: Contribution to journalArticle

Abstract

Achievement of MR4.5 (BCR-ABL1 ≤ 0.0032% on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This study describes treatment patterns by region and assesses time to achieve MR4.5 in patients with CML–chronic phase (CP) treated with second-line nilotinib or dasatinib in 10 countries. A multivariate Cox proportional hazards model was used to assess time to MR4.5 for nilotinib versus dasatinib. The model accounted for the competing-risk event of TKI resistance, included random effects for country clustering, and was adjusted for baseline covariates. The study included 280 patients treated with either nilotinib (N = 135 [48%]) or dasatinib (N = 145 [52%]) as second-line TKI with median treatment durations of 19.1 and 18.7 months, respectively. Nilotinib was observed to be better in achieving MR4.5 than dasatinib (adjusted hazard ratio = 1.37, 95% CI [1.11, 1.69]) suggesting second-line nilotinib may perform better in achieving MR4.5 than dasatinib.

Original languageEnglish (US)
Pages (from-to)98-107
Number of pages10
JournalLeukemia and Lymphoma
Volume61
Issue number1
DOIs
StatePublished - Jan 2 2020
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Therapeutics
Proportional Hazards Models
Cluster Analysis
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
Dasatinib

Keywords

  • Chronic myeloid leukemia
  • deep molecular response
  • nilotinib
  • targeted therapies
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib : a multi-country retrospective chart review study. / Cortes, Jorge; Huynh, Lynn; Mendelson, Estella; Brandt, Patricia; Dalal, Darshan; DerSarkissian, Maral; Cortina, Diego; Narkhede, Sahil; Sheng Duh, Mei.

In: Leukemia and Lymphoma, Vol. 61, No. 1, 02.01.2020, p. 98-107.

Research output: Contribution to journalArticle

Cortes, Jorge ; Huynh, Lynn ; Mendelson, Estella ; Brandt, Patricia ; Dalal, Darshan ; DerSarkissian, Maral ; Cortina, Diego ; Narkhede, Sahil ; Sheng Duh, Mei. / Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib : a multi-country retrospective chart review study. In: Leukemia and Lymphoma. 2020 ; Vol. 61, No. 1. pp. 98-107.
@article{4e56355e1f444586b2c446601a99ef14,
title = "Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study",
abstract = "Achievement of MR4.5 (BCR-ABL1 ≤ 0.0032{\%} on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This study describes treatment patterns by region and assesses time to achieve MR4.5 in patients with CML–chronic phase (CP) treated with second-line nilotinib or dasatinib in 10 countries. A multivariate Cox proportional hazards model was used to assess time to MR4.5 for nilotinib versus dasatinib. The model accounted for the competing-risk event of TKI resistance, included random effects for country clustering, and was adjusted for baseline covariates. The study included 280 patients treated with either nilotinib (N = 135 [48{\%}]) or dasatinib (N = 145 [52{\%}]) as second-line TKI with median treatment durations of 19.1 and 18.7 months, respectively. Nilotinib was observed to be better in achieving MR4.5 than dasatinib (adjusted hazard ratio = 1.37, 95{\%} CI [1.11, 1.69]) suggesting second-line nilotinib may perform better in achieving MR4.5 than dasatinib.",
keywords = "Chronic myeloid leukemia, deep molecular response, nilotinib, targeted therapies, tyrosine kinase inhibitor",
author = "Jorge Cortes and Lynn Huynh and Estella Mendelson and Patricia Brandt and Darshan Dalal and Maral DerSarkissian and Diego Cortina and Sahil Narkhede and {Sheng Duh}, Mei",
year = "2020",
month = "1",
day = "2",
doi = "10.1080/10428194.2019.1644332",
language = "English (US)",
volume = "61",
pages = "98--107",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Treatment patterns and deep molecular response in chronic phase–chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib

T2 - a multi-country retrospective chart review study

AU - Cortes, Jorge

AU - Huynh, Lynn

AU - Mendelson, Estella

AU - Brandt, Patricia

AU - Dalal, Darshan

AU - DerSarkissian, Maral

AU - Cortina, Diego

AU - Narkhede, Sahil

AU - Sheng Duh, Mei

PY - 2020/1/2

Y1 - 2020/1/2

N2 - Achievement of MR4.5 (BCR-ABL1 ≤ 0.0032% on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This study describes treatment patterns by region and assesses time to achieve MR4.5 in patients with CML–chronic phase (CP) treated with second-line nilotinib or dasatinib in 10 countries. A multivariate Cox proportional hazards model was used to assess time to MR4.5 for nilotinib versus dasatinib. The model accounted for the competing-risk event of TKI resistance, included random effects for country clustering, and was adjusted for baseline covariates. The study included 280 patients treated with either nilotinib (N = 135 [48%]) or dasatinib (N = 145 [52%]) as second-line TKI with median treatment durations of 19.1 and 18.7 months, respectively. Nilotinib was observed to be better in achieving MR4.5 than dasatinib (adjusted hazard ratio = 1.37, 95% CI [1.11, 1.69]) suggesting second-line nilotinib may perform better in achieving MR4.5 than dasatinib.

AB - Achievement of MR4.5 (BCR-ABL1 ≤ 0.0032% on international scale) is an important goal of tyrosine kinase inhibitor (TKI) treatment for patients with chronic myeloid leukemia (CML). This study describes treatment patterns by region and assesses time to achieve MR4.5 in patients with CML–chronic phase (CP) treated with second-line nilotinib or dasatinib in 10 countries. A multivariate Cox proportional hazards model was used to assess time to MR4.5 for nilotinib versus dasatinib. The model accounted for the competing-risk event of TKI resistance, included random effects for country clustering, and was adjusted for baseline covariates. The study included 280 patients treated with either nilotinib (N = 135 [48%]) or dasatinib (N = 145 [52%]) as second-line TKI with median treatment durations of 19.1 and 18.7 months, respectively. Nilotinib was observed to be better in achieving MR4.5 than dasatinib (adjusted hazard ratio = 1.37, 95% CI [1.11, 1.69]) suggesting second-line nilotinib may perform better in achieving MR4.5 than dasatinib.

KW - Chronic myeloid leukemia

KW - deep molecular response

KW - nilotinib

KW - targeted therapies

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85070889545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070889545&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1644332

DO - 10.1080/10428194.2019.1644332

M3 - Article

C2 - 31409168

AN - SCOPUS:85070889545

VL - 61

SP - 98

EP - 107

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -